Cat. No. | Product name | CAS No. |
DCC3049 |
Ldn-0028574
Novel Inhibitor of SIRT1; Inhibitor of the human MDM2-p53 interaction |
337500-87-5 |
DCC3050 |
Ldn-0044878
Novel PAK3 kinase inhibitor, inhibiting p53-inactivated cancers |
296246-47-4 |
DCC3051 |
Ldn-0070977
Novel inhibitor of PERK stress-dependent eIF2α phosphorylation with no toxicity to the cells |
|
DCC3052 |
Ldn-0130436
Novel TDP-43::GFP aggregation inhibitor |
|
DCC3053 |
ldn-112006
Necroptosis inhibitor |
1000878-74-9 |
DCC3054 |
Ldn-193188
Novel inhibitor of phosphatidylcholine transfer protein (PC-TP) |
1267610-30-9 |
DCC3055 |
ldn-193191
Potent and metabolically stable inhibitor of necroptosis, a regulated caspase-independent cell death pathway |
1395922-79-8 |
DCC3056 |
ldn-193594
Novel cdk5/p25 kinase inhibitor |
1289638-15-8 |
DCC3057 |
Ldn-193665
Novel potent tau kinase inhibitor, targeting CDK5/p25 and GSK3β |
1289638-16-9 |
DCC3058 |
ldn-211898
Potent haspin kinase inhibitor |
1342261-10-2 |
DCC3059 |
Ldn-213844
Novel ALK2 inhibitor |
|
DCC3060 |
Ldn-73794
Competitive LRRK2 kinase inhibitor without affecting the GTPase activity |
27318-90-7 |
DCC3061 |
L-dopa-snme3
Precursor of 6-[18F]Fluoro-L-DOPA used for positron emission tomography (PET) scans. References: http://www.hindawi.com/journals/bmri/2014/674063/ |
143993-90-2 |
DCC3062 |
Lds-751
Nucleic acid binding fluorescent dye |
76433-29-9 |
DCC3063 |
Ldt3 Dihydrochloride
Highly potent multi-target antagonists of both alpha1A- and alpha1D-adrenoceptors, and also of 5-HT1A receptors |
693227-88-2 |
DCC3064 |
Ldt409
Novel partial agonist of PPARα and PPARγ, providing distinct and favorable gene activation profiles for the treatment of diabetes and obesity |
|
DCC3065 |
Ldt5 Dihydrochloride
Highly potent multi-target antagonists of both alpha1A- and alpha1D-adrenoceptors, and also of 5-HT1A receptors |
110529-83-4 |
DCC3066 |
Ldt8 Dihydrochloride
Highly potent multi-target antagonists of alpha1A- and alpha1D-adrenoceptors, and 5-HT1A receptors |
|
DCC3067 |
Ledgf/p75-in Inhibitor-6d
Novel inhibitor of the LEDGF/p75-IN interaction, potently inhibiting both the early and late stages of HIV-1 replication |
|
DCC3068 |
Lefucoxib
Cyclooxygenase-2 (COX-2) inhibitor |
849048-84-6 |
DCC3069 |
Lei-101
Novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist |
1228660-00-1 |
DCC3070 |
Lei-301
Novel potent inhibitor for the PLAAT family members, reducing the NAE levels, including anandamide, in cells overexpressing PLAAT2 or PLAAT5 |
|
DCC3071 |
Lem-06
Novel inhibitor of nuclear receptor binding SET domain 2 (NSD2), against H3K36 methylation |
|
DCC3072 |
Lenaldekar
Novel inhibitor of T-cell expansion and autoimmune encephalomyelitis |
418800-15-4 |
DCC3073 |
Lenalidomide-slf
Novel Electrophilic PROTAC that degrades nuclear proteins by engaging DCAF16 |
|
DCC3074 |
Leniquinsin
Phosphodiesterase inhibitor, acting as a vasodilator and showing antihypertensive effects |
10351-50-5 |
DCC3075 |
Leo-134310
Novel non-steroidal glucocorticoid receptor agonist |
|
DCC3076 |
Leo-29102
Novel Soft-Drug Inhibitor of Phosphodiesterase 4 (PDE4) for Topical Treatment of Atopic Dermatitis |
1035572-38-3 |
DCC3077 |
Leq-506
Orally bioavailable Smoothened (Smo) antagonist |
1057677-92-5 |
DCC3078 |
Leucettamine A
Leukotriene B4 receptor antagonist |
151124-32-2 |
DCC3079 |
leucinethiol
Inhibitor of ERAAP function |
112157-33-2 |
DCC3080 |
Levallorphan Tartrate Salt
Partial agonist (antagonist) at mu and delta opioid receptors. |
71-82-9 |
DCC3081 |
Levcromakalim Phosphate
Watersoluble prodrug of Levcromakalim, being more chemically robust and efficacious at lowering IOP with once daily dosing in a normotensive mouse model. |
|
DCC3082 |
Levocarnitine Propionate Hydrochloride
Natural carnitine derivative, playing a role in mitochondrial metabolism and demonstrating beneficial cardiovascular effects |
119793-66-7 |
DCC3083 |
Levofloxacin Lactate
Respiratory quinolone antibiotic, exhibiting enhanced activity against the important respiratory pathogen Streptococcus pneumoniae |
294662-18-3 |
DCC3084 |
Ginsenoside Rg
Neuroprotective, anti-inflammatory, and anti-diabetic agent, protecting against DNA damage and apoptosis induced by ultraviolet light |
|
DCC3085 |
levormeloxifene Fumarate
Selective estrogen receptor modulator (SERM) |
199583-01-2 |
DCC3086 |
Lfcinb6
Hematologic malignancy-selective membranolytic peptide from the antimicrobial core (RRWQWR) of bovine lactoferricin |
|
DCC3087 |
Lfs-829
Novel potent and selective antagonist of exportin-1, attenuating dual NF-κB signaling and the Nrf2 cytoprotection pathway via targeting exportin-1 in colitis mice |
1799330-89-4 |
DCC3088 |
lg190178
Novel non-secosteroidal vitamin D receptor (VDR) ligand |
233268-81-0 |
DCC3089 |
Lgh00031
Novel irreversible inhibitor of cell division cycle 25B, inhibiting human cancer cells via ROS generation |
|
DCC3090 |
Lgh447 Hydrochloride
Potent and specific pan-PIM inhibitor, inhibiting proliferation of several AML cell lines, showing dual antitumoral and bone antiresorptive effects |
1210416-52-6 |
DCC3091 |
Lh65.3
Novel S. typhimurium infection inhibitor on the activity of DUSP3, DUSP11, and DUSP27 |
1494676-74-2 |
DCC3092 |
Lh-708
Novel inhibitor of cystine stone formation for treatment of cystinuria |
1616757-93-7 |
DCC3093 |
L-histidinol Dihydrochloride
Natural precursor of histamine; reversible inhibitor of protein synthesis |
1596-64-1 |
DCC3094 |
liafensine
Serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI); Anti-depressant |
1198790-53-2 |
DCC3095 |
liarozole Hydrochloride
Novel inhibitor of AMA1–RON2 interaction, blocking merozoite invasion from schizont-infected RBCs; Cytochrome P450 inhibitor |
145858-50-0 |
DCC3096 |
Lifibrate
Inhibitor of cholinephosphotransferase (CPT), phosphatidyl-N-methylethanolamine N-methyltransferase (PME-NMT), and phosphatidyl-N,N-dimethylethanolamine N-methyltransferase (PDE-NMT) |
22204-91-7 |
DCC3097 |
Liguzinediol
Potent positive inotropic agent, inhibiting myocardial cell apoptosis |
909708-65-2 |
DCC3098 |
Lin28-let-7 Inhibitor-1
Novel inhibitor of the oncogenic Lin28-let-7 interaction |
|
DCC3099 |
Linifolin A
Natural capsid inhibitor |
5988-99-8 |
DCC3100 |
Linker-payload 49
Novel Fused Benzodiazepine Hybrid Payload for Antibody-Drug Conjugate (ADC) |
|
DCC3101 |
Lintopride
5HT-4 antagonist with moderate 5HT-3 antagonist properties |
107429-63-0 |
DCC3102 |
Lipid Ii Binder 5107930
Lipid II binder, causing specific upregulation of the vancomycin-resistance associated gene vraX which is implicated in the cell wall stress stimulon that confers glycopeptide resistance |
|
DCC3103 |
Lipocrine
The first inhibitor of the catalytic activity of AChE and AChE-induced amyloid-beta aggregation protecting against reactive oxygen species |
844874-00-6 |
DCC3104 |
lisa-4
The first fluorogenic dipeptide probe for |
1638785-71-3 |
DCC3105 |
Lith-o-asp
Novel pan-inhibitor of sialyltransferase (ST) |
881179-02-8 |
DCC3106 |
Ljp-1586
Potent, selective, and orally active inhibitor of semicarbazide-sensitive amine oxidase (SSAO) activity, inhibiting vascular adhesion protein 1 (VAP-1) activity and decreasing the density of macrophages in inflamed atherosclerotic plaques in mice |
955037-42-0 |
DCC3107 |
lk 204-545
Highly |
83068-69-3 |
DCC3108 |
Lk-514
Featured
Novel selective agonist of the human melanocortin 1 receptor (hMC1R) for sunless tanning and prevention of genotoxicity of UV in melanocytes |
|
DCC3109 |
Ll4212
Novel inducer of biofilm dispersal, having a slower rate of NO release |
|
DCC3110 |
Lm-030
Novel inhibitor of kallikrein-related peptidase 7 (KLK7) and epidermal elastase 2 (ELA2) |
1122484-55-2 |
DCC3111 |
lm11a-24
Novel Modulator of p75NTR-dependent motor neuron death |
106522-85-4 |
DCC3112 |
lm11a-36
Negative control for LM11A-24 |
107152-00-1 |
DCC3113 |
Lm229
Novel Probe for Imaging Tau Pathology in Transgenic Mouse and Rat Models |
|
DCC3114 |
lm-24 Hydrochloride
Novel p75NTR antagonist |
109367-15-9 |
DCC3115 |
lmc-21
Novel AI-2 quorum-sensing inhibitor, affecting the starvation response and reducing virulence in several Vibrio species, most likely by interfering with LuxPQ |
168906-95-4 |
DCC3116 |
Lmptp-in-5d
Novel highly selective inhibitor of the low-molecular-weight protein tyrosine phosphatase (LMPTP), being highly orally bioavailable and reversing obesity-induced diabetes in mice |
|
DCC3117 |
Ln3844
Novel Two-in-One Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites |
|
DCC3118 |
lnp-509
Potent and selective ligand of imidazoline 1 receptor (I 1 R) |
341501-92-6 |
DCC3119 |
Lnp599 Hydrochloride
Novel potent and specific agonist of I 1 imidazoline receptors |
|
DCC3120 |
Lobeglitazone Sulfate
Featured
Peroxisome proliferator-activated receptor-α/γ (PPAR α/γ) dual agonist |
763108-62-9 |
DCC3121 |
Lobelane Hydrochloride
Inhibitor of the Vesicular_monoamine_transporter_2>vesicular monoamine transporter-2 (VMAT2) |
246244-19-9 |
DCC3122 |
Lomefloxacin
Antibiotic for treatment of bacterial infections including bronchitis and urinary tract infections, prevent urinary tract infections prior to surgery |
98079-51-7 |
DCC3123 |
Longanlactone
Natural neurotrophic agent |
|
DCC3124 |
Loperamide
Opioid receptor agonist, acting on the µ-opioid receptors in the myenteric plexus of the large intestine |
53179-11-6 |
DCC3125 |
Lopinavir M-3/m-4
Lopinavir Secondary Metabolite |
357275-54-8 |
DCC3126 |
Lox-activity Sensor-1
Novel LOX-activity sensor for cross-linking with a collagen peptide to chemoselectively target endogenous aldehydes generated by LOX |
|
DCC3127 |
Lp-20 Hydrochloride
Potent ligand of the 5-HT7 receptor |
1386928-34-2 |
DCC3128 |
Lp-261
Potent antimitotic and oral tubulin binding agent, significantly inhibiting growth of a human non-small-cell lung tumor |
915412-67-8 |
DCC3129 |
Lp-922761
Novel potent and selective peripheral AAK1 inhibitor |
1454808-95-7 |
DCC3130 |
Lp-925219
Novel inhibitor of both renal SGLT1 and SGLT2 |
|
DCC3131 |
Lpa1-3 Agonist Cpx
Novel LPA 1-3 agonist, inducing a calcium response in hLPA 1-3 cells within a range of 0.4 to 1.5-log lower potency, as compared to LPA |
|
DCC3132 |
Lpa1-3 Agonist Cpy
Novel LPA 1-3 agonist, inducing a calcium response in hLPA 1-3 cells within a range of 0.4 to 1.5-log lower potency, as compared to LPA |
|
DCC3133 |
Lqfm030
Novel p53 activator through the inhibition of MDM2 |
|
DCC3134 |
Lqmed 330
Novel potent and specific inhibitor of O-linked β-N-acetylglucosamine transferase (OGT) |
|
DCC3135 |
Lrh-1 Agonist 10ca
Novel agonist of liver receptor homolog-1 (LRH-1), reducing the expression of lipogenic genes in mouse liver, and inflammation and disease severity in a mouse model of ulcerative colitis |
|
DCC3136 |
Lrh-1 Agonist-6n
Novel potent agonist of the liver receptor homolog-1 (LRH-1, NR5A2) |
|
DCC3137 |
Lrh-1 Inhibitor-3
The first small molecule antagonist of LRH-1 activity. |
1185410-60-9 |
DCC3138 |
Lsd1 Inhibitor L8
Novel selective and reversible LSD1 inhibitor (IC50 value of 60 nM), exhibiting the antiproliferative activity against HTB5, HTB3, HT1376, and HTB1 cells with IC50 values of 1.87, 0.18, 0.09, and 0.93 μM, respectively |
|
DCC3139 |
Lsd1-in-c26
Novel selective inhibitor of histone lysine specific demethylase 1 (LSD1/KDM1A), displaying FAD-competitive binding to LSD1, concentration-dependently inducing accumulation of H3K4me1/me2 and H3K9me2, increasing expression levels of epithelial cell marker |
|
DCC3140 |
Lsf-oa
Novel prodrug of Lisofylline, maintaining a steady fasting blood glucose level with a significant increase in insulin level |
|
DCC3141 |
Lsf-pa
Novel prodrug of Lisofylline, maintaining a steady fasting blood glucose level with a significant increase in insulin level |
|
DCC3142 |
Lsm-4144
First-in-class inhibitor of NF-κB signaling pathway by preventing the maturation of a rate-limiting multiprotein complex necessary for IKK activation |
|
DCC3143 |
Lsn3160440
Novel positive allosteric modulator (PAM) of the GLP-1R, enhancing insulin secretion in a glucose-, ligand- and GLP-1R-dependent manner |
|
DCC3144 |
Lsn3172176 Precursor
Precursor for 11C-radiolabelling LSN3172176 PET scan |
|
DCC3145 |
Lsn335984 Trihydrochloride
Selective inhibitor of P-glycoproteins (P-gp) |
167356-37-2 |
DCC3146 |
Lspn451
Novel potent xanthine oxidase inhibitor |
474555-58-3 |
DCC3147 |
Lt-106-175
Novel potent inhibitor of FLT3 mutations, also inhibiting CDK2 and CDK6 |
1429515-49-0 |
DCC3148 |
Ethyl-3,4-dephostatin
Novel inhibitor of the interactions of CFTR-associated ligand (CAL) and PSD-95/Dlg1/ZO-1 (PDZ) domain |
237756-11-5 |
DCC3149 |
L-threonyl-l-threonine
Peptide metabolite |
96337-78-9 |
DCC3150 |
Lturm-36
Novel PI 3-kinase delta inhibitor |
1879887-94-1 |
DCC3151 |
Lu Aa27122
Brain penetrant high affinity α1A-adrenoceptor ligand |
|
DCC3152 |
Lu Aa41063
Novel potent and selective hA2A receptor antagonist |
851202-49-8 |
DCC3153 |
Lu Af58786
Novel potent and selective inhibitor of LRRK2, inhibiting LRRK2 WT, the overactive variant G2019S, and the resistant mutant A2016T56 at 12 nM, 19 nM and 93 nM, respectively |
1632368-13-8 |
DCC3154 |
Lu Af58801
Novel, potent, selective and brain penetrant positive allosteric modulator of alpha-7 nicotinic acetylcholine receptors |
1531592-40-1 |
DCC3155 |
Lu-001i
Novel potent and selective LMP2 inhibitor, also inhibiting mouse 20S proteasomes |
|
DCC3156 |
Lu-002
Novel β2-specific inhibitor, potently targeting both β2c and β2i, displaying moderate trypanocidal activity |
|
DCC3157 |
Lu-002c
Novel potent β2c-specific inhibitor, displaying moderate trypanocidal activity |
|
DCC3158 |
Lu-002i
Novel β2i-specific inhibitor, displaying moderate trypanocidal activity |
|
DCC3159 |
Lu-aa47070
Potent and selective adenosine A2A receptor antagonist |
913842-25-8 |
DCC3160 |
Lu-af11205
Potent mGlu5 receptor positive allosteric modulator (PAM) |
1290133-16-2 |
DCC3161 |
Luf-5764
A1 adenosine receptor antagonist |
820961-49-7 |
DCC3162 |
Luf-6056
Human adenosine A1 receptor antagonist |
|
DCC3163 |
Luf-6258
Hybrid ortho/allosteric ligand of the adenosine A(1) receptor |
|
DCC3164 |
Lugdunin
Thiazolidine-containing cyclic peptide antibiotic, suppressing growth of species of disease-causing bacteria in that part of the human microbiome |
1989698-37-4 |
DCC3165 |
Luminespib Mesylate
Novel inhibitor of heat shock protein 90 (Hsp90) |
1051919-26-6 |
DCC3166 |
Luminolate (luminol Sodium Salt)
Immune modulator with SARS-CoV-2 antiviral activity via a multi-target mechanism including localized, self-limiting reactive oxygen species (ROS) scavenging activities that were demonstrated in a model of lipopolysaccharide (LPS)-induced joint inflammatio |
20666-12-0 |
DCC3167 |
Lx7101 Hydrochloride
Novel Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma |
2319882-48-7 |
DCC3168 |
lxrβ-agonist-19
Novel selective LXRβ agonist, reducing total brain Aβ |
1370443-60-9 |
DCC3169 |
Lxy6006
Novel Manassantin A Derivative, Inhibiting Hypoxia-Inducible Factor 1 and Tumor Growth |
|
DCC3170 |
Lxy6090
Novel potent HIF-1 inhibitor, also downregulating the protein level of HIF-1alpha, which depended on von Hippel-Lindau for proteasome degradation, showing in vivo anticancer efficacy by decreasing the HIF-1alpha expression in nude mice bearing MX-1 tumor |
|
DCC3171 |
Ly2019-005
Novel LRRK2 kinase inhibitor against the wild-type and G2019S mutant LRRK2 kinase being 424.40 ± 1.31 nM, 378.80 ± 1.20 nM, respectively |
|
DCC3172 |
Ly2019-006
Novel LRRK2 kinase inhibitor against the wild-type and G2019S mutant LRRK2 kinase being 1526.00 ± 0.87 nM, 1165.00 ± 1.18 nM, respectively |
|
DCC3173 |
Ly2048978
Novel, potent, orally-bioavailable kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders |
676495-11-7 |
DCC3174 |
ly-2121260
Novel glucokinase activator (GKA) |
866484-00-6 |
DCC3175 |
ly-2140023
Novel mGlu2/3 receptor agonist; Prodrug of LY-404039 |
1026791-63-8 |
DCC3176 |
Ly-231617
Potent antioxidant, being cytoprotective in models of focal and global cerebral ischemia |
141545-89-3 |
DCC3177 |
Ly2389575
Selective negative allosteric modulator of mGlu3 |
885104-09-6 |
DCC3178 |
Ly-278584
Potent 5-HT3 serotonin receptor antagonist |
119193-37-2 |
DCC3179 |
ly2886721 Hydrochloride
Orally active cell-permeable inhibitor of human |
1262036-49-6 |
DCC3180 |
Ly2934747
Novel, potent, and systemically bioavailable mGlu2/3 receptor agonist, exhibiting both antipsychotic and analgesic properties in vivo |
1448707-43-4 |
DCC3181 |
ly-294002 Hydrochloride
Selective cell permeable phosphatidylinositol 3-kinase (PI3K) inhibitor |
934389-88-5 |
DCC3182 |
Ly2979165 Ammonium Salt
Novel highly potent and selective agonist of metabotropic glutamate (mGlu) receptors 2 and 3 |
1311385-32-6 |
DCC3183 |
Ly-333531 Mesylate
Potent and selective inhibitor of PKCβI and PKCβII |
192050-59-2 |
DCC3184 |
Ly339434
Potent GluR5 kainate receptor agonist |
219566-62-8 |
DCC3185 |
Ly382884
Selective GluR5 kainate receptor antagonist |
211566-75-5 |
DCC3186 |
Ly392098
AMPA receptor potentiator |
211311-66-9 |
DCC3187 |
Ly-395153
Allosteric modulator of AMPA receptors |
211313-51-8 |
DCC3188 |
Ly444711
Orally active ghrelin agonist, bindjng with high affinity to and being a potent activator of the growth hormone secretagogue receptor 1a (GHS-R1a) receptor |
220541-10-6 |
DCC3189 |
Ly451646
AMPA receptor potentiator |
507483-43-4 |
DCC3190 |
Ly456236 Hydrochloride
Selective mGlu1 receptor antagonist |
338738-57-1 |
DCC3191 |
Ly-465608
Novel potent and selective dual PPARalpha/gamma agonist |
328918-26-9 |
DCC3192 |
Ly-466195
Novel competitive GLUK5 receptor antagonist |
317844-33-0 |
DCC3193 |
Ly544344
Prodrug of LY354740, highly selective and potent agonist of group II mGlu receptors (mGluR2) |
441765-98-6 |
DCC3194 |
Ly-580276
Novel inhibitor of the type I transforming growth factor beta receptor (TβRI) |
476475-07-7 |
DCC3195 |
Lyc-31138
Novel F1F0-ATPase modulator, significantly decreasing M2 glutamate and increasing M4 glutamate |
1381806-47-8 |
DCC3196 |
Ly-hn2am
Nove fluorescent probe for highly sensitive monitoring drug induced lysosomal pH value changes, exhibiting good biological compatibility, low cytotoxicity and high resistance to photobleaching |
|
DCC3197 |
Lyngbyastatin 7
Natural Potent Marine-Derived Elastase Inhibitor |
|
DCC3198 |
Lysine Orotate
Inhibitor of viral replication, especially useful in the treatment of the Herpes family of viruses which includes Herpes Simplex 1 and 2 , EBV , CMV and Varicella. |
28003-86-3 |
DCC3199 |
Lyso-7
Inhibitor of cyclooxygenase (COX); Pan partial agonist of PPARγ, PPARα and PPARβ/δ |
1244215-18-6 |
DCC3200 |
Lzz-02
Novel inhibitor of the transcriptional activity of β-catenin, degrading the expression of β-catenin by stabilizing axin 2 and diminishing downstream proteins levels, including c-Myc and cyclin D1, effectively shrinking tumor xenograft derived from colonic |
5307-25-5 |
DCC3201 |
M-084 Hydrochloride
TRPC4/5 channel blocker, exhibiting antidepressant and anxiolytic effects |
51314-51-3 |
DCC3202 |
M1-pam-a
Novel selective muscarinic M1 receptor positive allosteric modulator, significantly improved scopolamine-induced cognitive deficits without prominent signs of diarrhea at up to 1000 mg/kg in mice |
|
DCC3203 |
M1-pam-b
Novel selective muscarinic M1 receptor positive allosteric modulator, showed both significant improvement of scopolamine-induced cognitive deficits and severe diarrhea |
|
DCC3204 |
M4k2009
Featured
M4K2209 is a potent, selective BMP type I receptor ALK2 inhibitor with IC50 of 9 nM, >180-fold selective over ALK5 (IC50=2427 nM). |
2600795-07-9 |
DCC3205 |
M4k2127
Novel potent and selective ALK2 inhibitor, showing high initial brain uptake, including in the region of interest (pons) |
|
DCC3206 |
M4k2163
Novel CNS Penetrant ALK2 Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma |
|
DCC3207 |
M-5mpep
Partial antagonist of mGlu5 |
872428-47-2 |
DCC3208 |
M7594_0037
Novel Peptide Deformylase (PDF) Inhibitor, having inhibitory activity against HeLa, A549 and MCF-7 |
774551-07-4 |
DCC3209 |
Mac-0547630
Novel potent and selective inhibitor of UppS without off-target effects on membrane potential |
950386-41-1 |
DCC3210 |
Mac13243
Novel inhibitor of the bacterial lipoprotein targeting chaperone, LolA |
1071638-38-4 |
DCC3211 |
Macluraxanthone
Natural immunomodulator, significantly decreasing TNF-α and IL-10 cytokine production, regulating the NF-κB and MAPK signaling pathways, displaying the strongest antiproliferative effects with IC50 values of 2.84 and 0.95 μM against A431 and HeLa cancer c |
5848-14-6 |
DCC3212 |
Madtp-372
Potent and selective inhibitor of the induction of cytopathic effect by CHIKV and VEEV |
|
DCC3213 |
Madurmycin
Polyether ionophore antibiotic, inhibiting proliferation and induces apoptosis in myoblast cells |
61991-54-6 |
DCC3214 |
Magl-2102
Novel reversible monoacylglycerol lipase (MAGL) inhibitor |
|
DCC3215 |
Magnesium L-threonate
Inhibitor of TNF-α, preventing and restoring memory deficits associated with neuropathic pain |
778571-57-6 |
DCC3216 |
Magnesium Oxaloacetate
Inhibitor of the amebicidal activity of activated murine macrophages, helping the parasite to survive within the mouse large intestine and increasing the survival of C. elegans exposed to H2O2 |
59866-21-6 |
DCC3217 |
Magreth-16a
Potent CB2 receptor inverse agonist |
|
DCC3218 |
Malonganenone A
Selective modulator of plasmodial Hsp70s with antimalarial activity |
882403-69-2 |
DCC3219 |
Malp-2
Toll-like receptor 2/6 (TLR-2/6) agonist, regulating Lcn2 gene, promoting collateral growth |
250718-44-6 |
DCC3220 |
Malp-2s
TLR2/6 agonist, activating the MyD88 pathway, provoking natural killer (NK) cell activation, increasing co-stimulators CD80/86 and CD40 |
|
DCC3221 |
Mal-rp
Novel quantitative chemical probe for live cell labeling and imaging of proteins that are sensitive to redox modifications |
1485456-25-4 |
DCC3222 |
Manassantin A
Natural anticancer, anti-inflammatory, neuroleptic agent, also having human acyl-CoA:cholesterol acyltransferase (ACAT) inhibitory activities |
88497-87-4 |
DCC3223 |
Mao-b Inhibitor 58
Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B). |
1619884-75-1 |
DCC3224 |
Mao-b Inhibitor C3
Novel potent and highly selective MAO-B Inhibitor |
|
DCC3225 |
Mao-b Inhibitor C5
Potent and selective MAO-B inhibitor |
1230-77-9 |
DCC3226 |
Mao-b Inhibitor Cc1
Novel potent selective and competitive inhibitor of MAO-B (IC 50 : 0.69 μM) |
140399-50-4 |
DCC3227 |
Mao-b Inhibitor Cc2
Novel potent and competitive inhibitor of MAO-B (IC 50 : 0.51 μM), also inhibiting BChE (IC 50 : 7.00 μM) |
|
DCC3228 |
Mao-b Ligand-1
Novel selective MAO-B inhibitor |
1010879-39-6 |
DCC3229 |
Ma-pabc-adc-linker-18
Novel stable antibody-drug conjugate (ADC) in mouse serum |
|
DCC3230 |
Maprotiline
Inhibitor of neuronal norepinephrine reuptake, reducing symptoms of anxiety associated with depression. |
10262-69-8 |
DCC3231 |
Marbotinib
Novel highly efficient dual type I/II FMS-like tyrosine kinase inhibitor, disrupting the growth of leukemic cells |
|
DCC3232 |
Margatoxin
Inhibitor of voltage-gated K(+) (Kv) channels Kv1.3 and Kv1.5 |
145808-47-5 |
DCC3233 |
Maritinone
Novel, active, and less toxic anti-tuberculosis (anti-TB) agent |
33927-59-2 |
DCC3234 |
Maropitant Citrate [359875-09-5]
Featured
Neurokinin receptor antagonist with antiemetic activity |
359875-09-5 |
DCC3235 |
Massiliamide
Novel potent tyrosinase inhibitor from the Gram-negative bacterium Massilia albidiflava DSM 17472T |
|
DCC3236 |
May1-in-13a
Novel potent inhibitor of May1 with Ki = 12 ± 1 nM, also inhibiting wild-type HIV-1 protease with Ki = 32 ± 5 pM and three drug resistance-associated mutants with Ki values ranging from 24 to 320 pM |
|
DCC3237 |
Maysin
Natural Anti-inflammation Agent, Attenuating Amyloid Plaques by Inducing Humoral Immune Response with Th2 Skewed Cytokine Response in the Tg (APPswe, PS1dE9) Alzheimer's Mouse Model |
70255-49-1 |
DCC3238 |
Mb-001
Novel potent inhibitor of the membrane-bound retinoid isomerase RPE65 |
|
DCC3239 |
Mb06322
Prodrug of MB05032, acting as potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes |
280782-97-0 |
DCC3240 |
Mb16695
Novel Inhibitor of Mycobacterium tuberculosis α-1,4-Glucan Branching Enzyme (GlgB) |
|
DCC3241 |
Mb-211
Novel inhibitor of dengue and West Nile virus NS2B-NS3 protease |
|
DCC3242 |
Mbls-in-5
Novel non-hemolytic and low toxic inhibitor of metallo-β-lactamases (MBLs), restoring the activity of meropenem against Escherichia coli, Citrobacter freundii, Proteus mirabilis and Klebsiella pneumonia, which carried resistance genes of blaNDM-1 |
|
DCC3243 |
Mbp-c12
Novel detergent, showing enhanced stability to all tested proteins compared to a gold standard detergent (DDM) |
|
DCC3244 |
Mbp-c9
Novel detergent, showing enhanced stability to all tested proteins compared to a gold standard detergent (DDM) |
|
DCC3245 |
Mbri-001
Deuterium-substituted anticancer agent, plinabulin, exhibiting better pharmacokinetic characteristics than that of plinabulin |
2054938-28-0 |
DCC3246 |
Mbt-fh Inhibitor-7
The first selective small molecule inhibitor of the Mycobacterium tuberculosis fumarate hydratase |
|
DCC3247 |
Mbx-1066
Potent antibacterial agent against a wide range of Gram-positive and Gram-negative bacteria |
868971-24-8 |
DCC3248 |
Mbx-1162
Novel antibacterial agent, remarkably potent against antibiotic-resistant bacterial strains such as MDR A. baumannii , ESBL-producing Klebsiella pneumoniae, VRE, and MRSA |
1225332-95-5 |